Drug Type Small molecule drug |
Synonyms Mosedipimod (USAN/INN), PLAG, EC-18 |
Target |
Mechanism CD4 agonists(T-cell surface antigen CD4 agonists), CD8 stimulants(Cluster of differentiation 8 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationBreakthrough Therapy (US), Orphan Drug (US), Fast Track (US) |
Molecular FormulaC39H70O6 |
InChIKeyGAKUNXBDVGLOFS-DUZKARGPSA-N |
CAS Registry221139-79-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dermatitis, Atopic | Phase 2 | - | 01 May 2025 | |
Respiratory Distress Syndrome, Acute | Phase 2 | US | 30 Apr 2021 | |
COVID-19 | Phase 2 | KR | 28 May 2020 | |
Mouth Neoplasms | Phase 2 | US | 03 Jul 2018 | |
Stomatitis | Phase 2 | US | 03 Jul 2018 | |
Advanced breast cancer | Phase 2 | KR | 30 Oct 2017 | |
Advanced cancer | Phase 2 | KR | 30 Oct 2017 | |
Chemotherapy-Induced Febrile Neutropenia | Phase 2 | KR | 30 Oct 2017 | |
Nonalcoholic Steatohepatitis | Phase 1 | - | - | |
Arthritis, Gouty | Preclinical | US | 20 Apr 2020 |
Phase 2 | 105 | ezjaxfilrj(lkrbrrglsb) = btegsnyrpa vztikgsoid (upbfeplgce ) View more | - | 02 Jun 2022 | |||
ezjaxfilrj(lkrbrrglsb) = jcetuyukkd vztikgsoid (upbfeplgce ) View more | |||||||
Not Applicable | 48 | (vglellvbjt) = there was a tendency that the PLAG group was comprised of relatively mild CIN whereas the control group was comprised of those with more severe CIN nhgakvdbet (gwkouyjxoq ) | - | 20 May 2015 | |||